PortfoliosLab logo
MIRM vs. TGTX
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between MIRM and TGTX is 0.40, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Performance

MIRM vs. TGTX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Mirum Pharmaceuticals, Inc. (MIRM) and TG Therapeutics, Inc. (TGTX). The values are adjusted to include any dividend payments, if applicable.

Loading data...

Key characteristics

Daily Std Dev

MIRM:

112.49%

TGTX:

53.63%

Max Drawdown

MIRM:

-7.13%

TGTX:

-10.72%

Current Drawdown

MIRM:

-2.14%

TGTX:

-10.72%

Fundamentals

Market Cap

MIRM:

$2.19B

TGTX:

$5.34B

EPS

MIRM:

-$1.61

TGTX:

$0.25

PS Ratio

MIRM:

5.77

TGTX:

13.82

PB Ratio

MIRM:

9.39

TGTX:

22.51

Total Revenue (TTM)

MIRM:

$379.25M

TGTX:

$265.53M

Gross Profit (TTM)

MIRM:

$292.42M

TGTX:

$232.41M

EBITDA (TTM)

MIRM:

-$33.56M

TGTX:

$57.77M

Returns By Period


MIRM

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

5Y*

N/A

10Y*

N/A

TGTX

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

MIRM vs. TGTX — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

MIRM
The Risk-Adjusted Performance Rank of MIRM is 8989
Overall Rank
The Sharpe Ratio Rank of MIRM is 9090
Sharpe Ratio Rank
The Sortino Ratio Rank of MIRM is 8888
Sortino Ratio Rank
The Omega Ratio Rank of MIRM is 8585
Omega Ratio Rank
The Calmar Ratio Rank of MIRM is 9494
Calmar Ratio Rank
The Martin Ratio Rank of MIRM is 9090
Martin Ratio Rank

TGTX
The Risk-Adjusted Performance Rank of TGTX is 8989
Overall Rank
The Sharpe Ratio Rank of TGTX is 9292
Sharpe Ratio Rank
The Sortino Ratio Rank of TGTX is 8989
Sortino Ratio Rank
The Omega Ratio Rank of TGTX is 8686
Omega Ratio Rank
The Calmar Ratio Rank of TGTX is 8383
Calmar Ratio Rank
The Martin Ratio Rank of TGTX is 9595
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

MIRM vs. TGTX - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Mirum Pharmaceuticals, Inc. (MIRM) and TG Therapeutics, Inc. (TGTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.



Loading data...

Dividends

MIRM vs. TGTX - Dividend Comparison

Neither MIRM nor TGTX has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

MIRM vs. TGTX - Drawdown Comparison

The maximum MIRM drawdown since its inception was -7.13%, smaller than the maximum TGTX drawdown of -10.72%. Use the drawdown chart below to compare losses from any high point for MIRM and TGTX. For additional features, visit the drawdowns tool.


Loading data...

Volatility

MIRM vs. TGTX - Volatility Comparison


Loading data...

Financials

MIRM vs. TGTX - Financials Comparison

This section allows you to compare key financial metrics between Mirum Pharmaceuticals, Inc. and TG Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0050.00M100.00M150.00M20212022202320242025
111.59M
108.19M
(MIRM) Total Revenue
(TGTX) Total Revenue
Values in USD except per share items

MIRM vs. TGTX - Profitability Comparison

The chart below illustrates the profitability comparison between Mirum Pharmaceuticals, Inc. and TG Therapeutics, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

40.0%50.0%60.0%70.0%80.0%90.0%100.0%20212022202320242025
79.4%
85.8%
(MIRM) Gross Margin
(TGTX) Gross Margin
MIRM - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Mirum Pharmaceuticals, Inc. reported a gross profit of 88.57M and revenue of 111.59M. Therefore, the gross margin over that period was 79.4%.

TGTX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, TG Therapeutics, Inc. reported a gross profit of 92.79M and revenue of 108.19M. Therefore, the gross margin over that period was 85.8%.

MIRM - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Mirum Pharmaceuticals, Inc. reported an operating income of -15.18M and revenue of 111.59M, resulting in an operating margin of -13.6%.

TGTX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, TG Therapeutics, Inc. reported an operating income of 29.95M and revenue of 108.19M, resulting in an operating margin of 27.7%.

MIRM - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Mirum Pharmaceuticals, Inc. reported a net income of -14.68M and revenue of 111.59M, resulting in a net margin of -13.2%.

TGTX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, TG Therapeutics, Inc. reported a net income of 23.33M and revenue of 108.19M, resulting in a net margin of 21.6%.